Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sovaldi Aside, Declining Economic Returns On New Drugs Threaten Innovation – Study

Executive Summary

Lifetime total costs exceeded expected revenues for novel products launched from 2005-2009, according to a paper published in Health Affairs. Focusing solely on recent successful launches like Gilead’s hepatitis C drug ignores the commercial fate of other once-promising drugs that turned out to be “dogs,” MIT researcher says.

You may also be interested in...



Head Of The Class: A Star Stands Out Among 2014 Drug Launches

Gilead’s Sovaldi earned a spot in the record books – and the hearts of drug marketers – generating $8.55 billion in the first nine months of 2014. Despite controversy over Sovaldi’s high price, Gilead defended the drug’s value and executed flawlessly on the launch. Other 2014 drug launches were slow out of the gates, as the bar for new drugs continues to grow.

US CDC Panel Moves To Simplify Pfizer/BioNTech, Moderna COVID-19 Vaccine Booster Recommendations

Citing considerations of simplification, implementation and equity, Advisory Committee on Immunization Practices says everyone ages ≥50 years should get an mRNA vaccine booster dose and recommends all individuals ≥18 years have the option of getting one, without regard to occupational exposure or underlying medical conditions.

Same Data, Broader Use: COVID-19 mRNA Vaccine Booster Authorizations Expanded In US

Emergency use authorization for Pfizer/BioNTech, Moderna vaccine boosters for everyone ≥18 years was based on the same immune response data that supported previous clearance in certain high-risk groups, although FDA said it also considered additional real-world data on myocarditis risk and the recent increase in COVID-19 cases.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel